Weidenauer, K. (2022). Identification of RPS6KA1 as a mediator of resistance to Venetoclax/Azacytidine-combination treatment in Acute Myeloid Leukemia by genome-scale CRISPR/Cas9 knockout screening.
Chicago-Zitierstil (17. Ausg.)Weidenauer, Katharina. Identification of RPS6KA1 as a Mediator of Resistance to Venetoclax/Azacytidine-combination Treatment in Acute Myeloid Leukemia by Genome-scale CRISPR/Cas9 Knockout Screening. Heidelberg, 2022.
MLA-Zitierstil (9. Ausg.)Weidenauer, Katharina. Identification of RPS6KA1 as a Mediator of Resistance to Venetoclax/Azacytidine-combination Treatment in Acute Myeloid Leukemia by Genome-scale CRISPR/Cas9 Knockout Screening. 2022.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.